trending Market Intelligence /marketintelligence/en/news-insights/trending/UDbfxVUQcnE-yPQ27S2LXQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Kino Biotech Q1 profit falls YOY

The Evolution Of ESG Factors In Credit Risk Assessment: Corporate Governance

Industry Top Trends 2021: Metals and Mining

TMT News & Research: 2020 Recap


Charter, DIRECTV and Comcast rank as the top 'RSN-friendly' MVPDs

Kino Biotech Q1 profit falls YOY

Kino Biotech Co. Ltd. said its first-quarter normalized net income amounted to 9 Taiwan cents per share, a decrease of 24.5% from 12 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$1.8 million, a decrease of 31.9% from NT$2.6 million in the prior-year period.

The normalized profit margin declined to 1.7% from 2.5% in the year-earlier period.

Total revenue increased on an annual basis to NT$106.2 million from NT$102.3 million, and total operating expenses increased 6.6% year over year to NT$105.6 million from NT$99.1 million.

Reported net income fell 29.1% from the prior-year period to NT$2.6 million, or 13 cents per share, from NT$3.7 million, or 17 cents per share.

As of May 15, US$1 was equivalent to NT$30.44.